A novel product for tendinopathy treatment

一种治疗肌腱病的新产品

• 批准号: 10306057
• 负责人: David T Fung
• 金额: $ 2.03万
• 依托单位: NEW YORK/R&D/CTR/TRANSLATIONAL MED/THER
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-15 至 2022-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10306057
• 关键词: Adverse effects; Award; Bioinformatics; Biological Response Modifier Therapy; Chronic; Data; Deterioration; Disease; Goals; Impairment; Pain; Parents; Pathology; Performance; Research Personnel; Swelling; Technology; Tendinopathy; Tendon structure; Testing; Therapeutic Effect; career development; commercialization; effective therapy; novel; pain symptom; research and development; tendon rupture; training opportunity; transcriptome; transcriptome sequencing; transcriptomics

Project Summary Tendinopathy is a tendon disorder characterized by tendon deterioration that often leads to tendon rupture, and is associated with pain, swelling and impaired performance. There is currently no cure for tendinopathy. Therefore, there is an urgent need for effective treatments for tendinopathy. The parent award is focused on testing the TenoGen, the product to be developed, exerts a therapeutic effect in mitigating tendinopathy pathology and relieving tendinopathy-related pain and symptoms with no or minimal adverse effects. The purpose of this supplement project is to provide support for an underrepresented researcher to participate and contribute to the R&D of TenoGen within the scope of the parent study. The supplement study will focus on establishing the transcriptome profile of TenoGen treatment using state-of-the-art transcriptomic RNA sequencing (RNA-seq) and bioinformatics technologies. Successful completion of the proposed supplement project is expected to not only provide additional data to accelerate for the R&D and commercialization of TenoGen, but also provide valuable support and an unique opportunity for the candidate’s career development. 1

项目摘要 肌腱病是一种肌腱疾病，其特征是肌腱退化，经常导致肌腱断裂， 与疼痛、肿胀和表现受损有关。目前还没有治愈肌腱病。 因此，迫切需要有效的治疗肌腱病。家长奖的重点是 测试TenoGen，即将开发的产品，在减轻肌腱病方面发挥治疗作用 病理学和减轻肌腱病相关的疼痛和症状，而没有或只有最小的副作用。的 该补充项目的目的是为代表性不足的研究人员提供支持， 在母研究范围内为TenoGen的研发做出贡献。补充研究将侧重于 使用最先进的转录组RNA建立TenoGen治疗的转录组谱 测序（RNA-seq）和生物信息学技术。圆满完成拟议补编 该项目预计不仅将提供额外的数据，以加快研发和商业化的 TenoGen同时也为应聘者的职业发展提供了宝贵的支持和独特的机会。 1